These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 19950171)
1. Direct antigen presentation by DC shapes the functional CD8(+) T-cell repertoire against the nuclear self-antigen La-SSB. Keech CL; Pang KC; McCluskey J; Chen W Eur J Immunol; 2010 Feb; 40(2):330-8. PubMed ID: 19950171 [TBL] [Abstract][Full Text] [Related]
2. Basophils can directly present or cross-present antigen to CD8 lymphocytes and alter CD8 T cell differentiation into IL-10-producing phenotypes. Kim S; Shen T; Min B J Immunol; 2009 Sep; 183(5):3033-9. PubMed ID: 19667092 [TBL] [Abstract][Full Text] [Related]
3. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC. Sugihara S; Fujiwara H; Niimi H; Shearer GM J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527 [TBL] [Abstract][Full Text] [Related]
4. Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8+ T cells. Schildknecht A; Probst HC; McCoy KD; Miescher I; Brenner C; Leone DP; Suter U; Ohashi PS; van den Broek M Eur J Immunol; 2009 Jun; 39(6):1505-15. PubMed ID: 19462379 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. Guéry JC; Adorini L J Immunol; 1995 Jan; 154(2):536-44. PubMed ID: 7529278 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. Ferlazzo G; Wesa A; Wei WZ; Galy A J Immunol; 1999 Oct; 163(7):3597-604. PubMed ID: 10490952 [TBL] [Abstract][Full Text] [Related]
7. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Lapenta C; Santini SM; Spada M; Donati S; Urbani F; Accapezzato D; Franceschini D; Andreotti M; Barnaba V; Belardelli F Eur J Immunol; 2006 Aug; 36(8):2046-60. PubMed ID: 16856207 [TBL] [Abstract][Full Text] [Related]
8. Inclusion of Brefeldin A during dendritic cell isolation allows in vitro detection of cross-presented self-antigens. Benke D; Krüger T; Lang A; Hamilton-Williams EE; Kurts C J Immunol Methods; 2006 Mar; 310(1-2):12-9. PubMed ID: 16510151 [TBL] [Abstract][Full Text] [Related]
9. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens. Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148 [TBL] [Abstract][Full Text] [Related]
10. Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. Lorenzi S; Mattei F; Sistigu A; Bracci L; Spadaro F; Sanchez M; Spada M; Belardelli F; Gabriele L; Schiavoni G J Immunol; 2011 May; 186(9):5142-50. PubMed ID: 21441457 [TBL] [Abstract][Full Text] [Related]
11. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1. Klotz L; Hucke S; Thimm D; Classen S; Gaarz A; Schultze J; Edenhofer F; Kurts C; Klockgether T; Limmer A; Knolle P; Burgdorf S J Immunol; 2009 Jul; 183(1):129-36. PubMed ID: 19535643 [TBL] [Abstract][Full Text] [Related]
12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294 [TBL] [Abstract][Full Text] [Related]
13. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504 [TBL] [Abstract][Full Text] [Related]